Mar
24
Forest Laboratories, maker of the selective serotonin reuptake inhibitorLexapro (escitalopram oxalate), announced on March 20, 2009 that the FDA had approved the drug for the acute and maintenance treatment of major depression in adolescents 12-17 years of age.
The Associated Press reported last month that the Justice Department had filed a complaint against Forest Laboratories alleging that they had been promoting the off-label use
Read the rest of this entry
